Clinical Trials Browser

Neoplasms × trastuzumab deruxtecan × 90 days × Clear all

NCT07022483 2026-05-28

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms

NCT07454668 2026-03-06

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Phase 1 Not yet recruiting

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Neoplasms